RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board
RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial
RhoVac publishes research results prior ASCO's meeting
RhoVac Participates in BIO Europe Digital
RhoVac AB | Aktiespararna
RhoVac AB will be transferred to Spotlight Stock Market's observation list
Market Notice 56/22 - Last day of trading in RhoVac AB's BTU
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac — Good execution in challenging times for industry - Edison Group
Share Information | Chosa Oncology
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
Market Notice 23/22 – Information regarding the rights issue from Rhovac AB
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac's CEO, Anders Månsson, has tendered his resignation
Market notice 94/22 – RhoVac AB´s financial instruments are moved to the Observation List
The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac's events during May - August
Another clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer
RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac AB receives approval to start clinical phase IIb study in Denmark
RhoVac's reports positive results from the 12 months follow-up of the company's phase I/II clinical study
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
